{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -2.913753, "regularMarketPrice": 16.66, "exchange": "FRA", "shortName": "VIVORYON THERAPEUTICS", "longName": "Vivoryon Therapeutics N.V.", "messageBoardId": "finmb_137369", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "marketState": "REGULAR", "esgPopulated": false, "sharesOutstanding": 24105300, "bookValue": 1.1, "fiftyDayAverage": 14.4092, "fiftyDayAverageChange": 2.2508001, "fiftyDayAverageChangePercent": 0.15620577, "twoHundredDayAverage": 11.16275, "twoHundredDayAverageChange": 5.4972496, "twoHundredDayAverageChangePercent": 0.49246374, "marketCap": 401594304, "priceToBook": 15.145454, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Vivoryon Therapeutics AG", "nameChangeDate": "2023-05-11", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1414652400000, "priceHint": 2, "regularMarketChange": -0.5, "regularMarketTime": 1683892793, "regularMarketDayHigh": 16.66, "regularMarketDayRange": "16.3 - 16.66", "regularMarketDayLow": 16.3, "regularMarketVolume": 60, "regularMarketPreviousClose": 17.16, "bid": 16.24, "ask": 16.58, "fullExchangeName": "Frankfurt", "financialCurrency": "EUR", "regularMarketOpen": 16.3, "averageDailyVolume3Month": 492, "averageDailyVolume10Day": 1326, "fiftyTwoWeekLowChange": 9.82, "fiftyTwoWeekLowChangePercent": 1.4356724, "fiftyTwoWeekRange": "6.84 - 19.5", "fiftyTwoWeekHighChange": -2.8400002, "fiftyTwoWeekHighChangePercent": -0.14564103, "fiftyTwoWeekLow": 6.84, "fiftyTwoWeekHigh": 19.5, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.62, "symbol": "05Y.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Weinbergweg 22", "city": "Halle", "zip": "06120", "country": "Germany", "phone": "49 345 555 9900", "website": "https://www.vivoryon.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ulrich  Dauer Ph.D.", "age": 57, "title": "Chairman of the Management Board, CEO & Exec. Director", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 373000, "fmt": "373k", "longFmt": "373,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Florian  Schmid", "age": 47, "title": "CFO, Member of Management Board & Exec. Director", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 251000, "fmt": "251k", "longFmt": "251,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Schaeffer Ph.D.", "age": 53, "title": "Chief Bus. Officer, Member of the Management Board & Exec. Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 315000, "fmt": "315k", "longFmt": "315,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Manuela  Bader", "title": "Director of Investor Relations & Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Frank T. Weber M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Konrad  Glund", "age": 69, "title": "Co-Founder & Advisor", "yearBorn": 1953, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hendrik  Liebers", "age": 51, "title": "Advisor", "yearBorn": 1971, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}